In cancer, PRMT5 is known to interact with cancer-associated deregulated pathways such as ErbB, FGF/FGFR signaling pathways and, for this reason, is considered a promising therapeutic target for the treatment of cancer (Sheng and Wang, 2016). Here, PRMT5 is linked to cancer.